Why CAC and LTV are More Complex in MedTech SaaS

Customer acquisition cost (CAC) and lifetime value (LTV) are standard SaaS metrics, but they carry extra weight — and extra complexity — in MedTech SaaS, where sales cycles are longer, buying committees are larger, and the path to revenue often runs through clinical and procurement stakeholders who don’t exist in a typical B2B software sale.

Why MedTech Sales Cycles Complicate CAC

A MedTech SaaS sale often involves clinical validation, procurement review, IT security assessment, and sometimes a pilot period before a contract is even signed. Each of those steps adds cost and time to the acquisition process, which means CAC in MedTech is often meaningfully higher than in more transactional SaaS categories — and needs to be modeled with that reality in mind rather than compared directly to general SaaS benchmarks.

Why LTV Needs a Longer Time Horizon

Because switching costs in MedTech environments tend to be high — clinical workflows are built around specific tools, and procurement cycles for replacing them are slow — customer relationships in this space often last considerably longer than in general SaaS. That can make lifetime value higher, but only if churn assumptions are modeled realistically for the sector rather than borrowed from shorter-cycle SaaS categories where customer relationships turn over more quickly.

Practical Considerations for Calculating These Metrics

Include the full cost of the sales cycle in CAC — clinical validation support, procurement documentation, security questionnaires — not just marketing and sales compensation.
Segment CAC and LTV by customer type (health system, physician practice, ambulatory center, etc.), since acquisition cost and retention can vary significantly across these segments.
Model payback period explicitly, since a longer CAC payback period is common in this space and needs to be planned for in cash flow forecasting rather than treated as a red flag by default.
Revisit LTV assumptions periodically as your customer base matures, since early cohorts may not be representative of retention patterns once the product and market fit have stabilized.

Communicating This to Investors

Investors familiar with MedTech generally understand that CAC will look higher and payback periods longer than in typical SaaS — what they’re usually evaluating is whether the LTV, driven by long retention and expansion within a health system, ultimately justifies that upfront cost. Framing your unit economics with sector-appropriate context, rather than against generic SaaS benchmarks, tends to lead to a more productive conversation.

A Composite Example

Consider a fictionalized MedTech SaaS company selling a clinical workflow tool to hospital systems. Its CAC, measured the way a typical B2B SaaS company would measure it — sales and marketing spend divided by new customers — looked alarmingly high compared to general SaaS benchmarks the founders had seen online. Once the team included the full cost of the sales cycle, including clinical pilot support and security review documentation, and compared that CAC against an LTV built on a realistic multi-year retention assumption specific to hospital procurement behavior, the picture looked considerably healthier: a longer payback period, but a stronger long-term return per customer than the initial, apples-to-oranges comparison had suggested.

Segmenting by Buyer Type

Because MedTech customers can range from small physician practices to large integrated health systems, blending all customer types into a single CAC or LTV figure can obscure important differences in acquisition cost and retention behavior. Segmenting by buyer type — and tracking unit economics separately for each — often reveals that certain segments are considerably more efficient to acquire and retain than others, which can meaningfully sharpen go-to-market strategy and where sales resources are focused.

Revisiting Assumptions as the Business Matures

Early LTV assumptions are often built on a small number of reference customers or educated estimates about retention, simply because there isn’t yet enough history to calculate churn reliably. As your customer base matures, it’s worth revisiting these assumptions with actual cohort data rather than continuing to rely on early estimates, since retention patterns in MedTech can look quite different once contracts move past their first renewal cycle and initial adoption risk has passed.

The Multi-Stakeholder Buying Process and Its Cost Implications

Unlike a typical SaaS sale that might involve a single decision-maker, a MedTech sale often requires separate buy-in from clinical staff, IT and security teams, procurement, and sometimes compliance or legal — each with their own evaluation criteria and timeline. This multi-stakeholder process is a major reason CAC tends to run higher in MedTech, since sales and customer success teams often need to produce different materials, run different demonstrations, and answer different sets of questions for each stakeholder group involved in a single deal.

Understanding which stakeholder group tends to cause the most delay or require the most resource-intensive support can help a company invest more precisely in reducing CAC — for example, building standardized security documentation once rather than recreating it for every IT review, or developing a clinical validation packet that can be reused across similar prospective customers rather than built from scratch each time. Small efficiency gains at each stage of a multi-stakeholder process can meaningfully improve overall CAC once compounded across a full sales pipeline.

Bringing It Back to the Forecast

Ultimately, well-segmented and sector-appropriate CAC and LTV figures feed directly into a more credible financial forecast — one that reflects realistic payback timelines rather than borrowed general SaaS assumptions. That accuracy tends to matter most exactly when it’s needed most: during a fundraise, when investors are testing whether the underlying unit economics can support the growth plan being presented to them.

A Final Note on Patience

Founders coming from faster-cycle software backgrounds sometimes get discouraged by MedTech unit economics that look worse than what they’re used to, without recognizing that longer payback periods are often simply the nature of the sector rather than a sign of a broken business model. Understanding and communicating that context — clearly, and backed by realistic retention data — tends to matter more than trying to force MedTech unit economics to resemble a faster-cycle SaaS benchmark they were never going to match.

CAC and LTV matter in every SaaS business, but in MedTech they need to be interpreted through the lens of longer sales cycles, larger buying committees, and higher switching costs. Modeling them with that context in mind, rather than against general SaaS benchmarks, gives a much more accurate read on the health of the business.

————————

About Herod CPA PLLC

Herod CPA PLLC provides forecasting, budgeting, and financial modeling services to SaaS startups within the cybersecurity and MedTech sectors.